Comtan, Stalevo Not Linked To Cardiovascular Risks: FDA
FDA investigators have found no clear link between heart attack risk and the Parkinson's disease drugs Stalevo and Comtan following a five-year review.
FDA investigators have found no clear link between heart attack risk and the Parkinson's disease drugs Stalevo and Comtan following a five-year review.
Federal drug reviewers have launched a safety review into the potential side effects of Stalevo, a Parkinson’s disease drug that may increase the risk of heart problems.
Federal drug reviewers say they have concerns that the side effects of Stalevo, a Parkinson’s disease medication by Novartis, may increase the risk of prostate cancer.